Julien Meissonnier - Catalent VP Officer

0C8 Stock  EUR 59.93  0.29  0.48%   

Insider

Julien Meissonnier is VP Officer of Catalent
Phone732 537 6200
Webhttps://www.catalent.com

Catalent Management Efficiency

The company has return on total asset (ROA) of 0.041 % which means that it generated a profit of $0.041 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.0873 %, meaning that it generated $0.0873 on every $100 dollars invested by stockholders. Catalent's management efficiency ratios could be used to measure how well Catalent manages its routine affairs as well as how well it operates its assets and liabilities.
Catalent has accumulated 4.17 B in total debt with debt to equity ratio (D/E) of 134.9, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Catalent has a current ratio of 2.14, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist Catalent until it has trouble settling it off, either with new capital or with free cash flow. So, Catalent's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Catalent sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Catalent to invest in growth at high rates of return. When we think about Catalent's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

INSIDER Age

Kathleen VeitTeva Pharmaceutical Industries
N/A
Norimasa TakedaTakeda Pharmaceutical
N/A
Isao TeshirogiShionogi Co
64
Deepak MBADr Reddys Laboratories
48
Torbjrn HallbergSwedish Orphan Biovitrum
54
Stephan GagneIpsen SA
N/A
Wafaa MamilliZoetis Inc
56
Dominique BeryIpsen SA
52
Amir WeissTeva Pharmaceutical Industries
46
Kare SchultzTeva Pharmaceutical Industries
62
Gabriele RicciTakeda Pharmaceutical
45
Yoshihiro FuruyaShionogi Co
N/A
Christine WesstromSwedish Orphan Biovitrum
48
Mark SabagTeva Pharmaceutical Industries
52
Susumu MitsumoriShionogi Co
N/A
Iwaaki TaniguchiTakeda Pharmaceutical
N/A
Nadeem SarwarEisai Co
N/A
Steven FrankZoetis Inc
N/A
Andrew PlumpTakeda Pharmaceutical
58
Henrik StenqvistSwedish Orphan Biovitrum
55
Guido OelkersSwedish Orphan Biovitrum
58
Catalent, Inc. provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products worldwide. Catalent, Inc. was founded in 2007 and is headquartered in Somerset, New Jersey. Catalent operates under Drug Manufacturers - Specialty Generic classification in Germany and is traded on Frankfurt Stock Exchange. It employs 11000 people. Catalent (0C8) is traded on Frankfurt Exchange in Germany and employs 19,000 people.

Management Performance

Catalent Leadership Team

Elected by the shareholders, the Catalent's board of directors comprises two types of representatives: Catalent inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Catalent. The board's role is to monitor Catalent's management team and ensure that shareholders' interests are well served. Catalent's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Catalent's outside directors are responsible for providing unbiased perspectives on the board's policies.
Thomas Castellano, VP CFO
Paul Surdez, VP Relations
Steven Esq, Corp VP
Julien Meissonnier, VP Officer
Karen Santiago, VP Office
Ricky Hopson, Pres Supply
Charles Lickfold, VP Officer
Aristippos Gennadios, President - Softgel Technologies
John Chiminski, Chairman of the Board and Presidentident, CEO
Alessandro Maselli, Senior Vice President - Global Operations

Catalent Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Catalent a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Currently Active Assets on Macroaxis

Additional Information and Resources on Investing in Catalent Stock

When determining whether Catalent is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Catalent Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Catalent Stock. Highlighted below are key reports to facilitate an investment decision about Catalent Stock:
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Catalent. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
For more detail on how to invest in Catalent Stock please use our How to Invest in Catalent guide.
You can also try the Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.
Please note, there is a significant difference between Catalent's value and its price as these two are different measures arrived at by different means. Investors typically determine if Catalent is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Catalent's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.